Induction of autoantibody production but not autoimmune disease in HEL transgenic mice vaccinated with HEL in combination with CpG or control oligodeoxynucleotides (Q47356352)

From Wikidata

Jump to navigation Jump to search

scientific article published in June 2004

Language	Label	Description	Also known as
English	Induction of autoantibody production but not autoimmune disease in HEL transgenic mice vaccinated with HEL in combination with CpG or control oligodeoxynucleotides	scientific article published in June 2004

Statements

scholarly article

1 reference

Europe PubMed Central

14 January 2018

http://europepmc.org/abstract/MED/15193390

Induction of autoantibody production but not autoimmune disease in HEL transgenic mice vaccinated with HEL in combination with CpG or control oligodeoxynucleotides (English)

1 reference

Europe PubMed Central

14 January 2018

http://europepmc.org/abstract/MED/15193390

1 reference

based on heuristic

inferred from title

autoimmune disease

1 reference

based on heuristic

inferred from title

author name string

Yiqiang Wang

1

1 reference

Europe PubMed Central

14 January 2018

http://europepmc.org/abstract/MED/15193390

Arthur M Krieg

2

1 reference

Europe PubMed Central

14 January 2018

http://europepmc.org/abstract/MED/15193390

language of work or name

0 references

publication date

1 June 2004

1 reference

Europe PubMed Central

14 January 2018

http://europepmc.org/abstract/MED/15193390

1 reference

Europe PubMed Central

14 January 2018

http://europepmc.org/abstract/MED/15193390

22

1 reference

Europe PubMed Central

14 January 2018

http://europepmc.org/abstract/MED/15193390

20

1 reference

Europe PubMed Central

14 January 2018

http://europepmc.org/abstract/MED/15193390

2641-2650

1 reference

Europe PubMed Central

14 January 2018

http://europepmc.org/abstract/MED/15193390

CpG motifs in bacterial DNA trigger direct B-cell activation

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.055

7 January 2021

CpG motifs in bacterial DNA and their immune effects

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.055

7 January 2021

CpG DNA as a Th1-promoting adjuvant in immunization against Trypanosoma cruzi

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.055

7 January 2021

Immunostimulatory CpG motifs trigger a T helper-1 immune response to human immunodeficiency virus type-1 (HIV-1) gp 160 envelope proteins

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.055

7 January 2021

CpG oligodeoxynucleotide enhances immunity against blood-stage malaria infection in mice parenterally immunized with a yeast-expressed 19 kDa carboxyl-terminal fragment of Plasmodium yoelii merozoite surface protein-1 (MSP1(19)) formulated in oil-ba

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.055

7 January 2021

CpG DNA overcomes hyporesponsiveness to hepatitis B vaccine in orangutans

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.055

7 January 2021

Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.055

7 January 2021

Parenteral and mucosal prime-boost immunization strategies in mice with hepatitis B surface antigen and CpG DNA

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.055

7 January 2021

CpG oligodeoxynucleotides with hepatitis B surface antigen (HBsAg) for vaccination in HBsAg-transgenic mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.055

7 January 2021

A phase I study of the safety and immunogenicity of recombinant hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide adjuvant

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.055

7 January 2021

CpG DNA induces stronger immune responses with less toxicity than other adjuvants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.055

7 January 2021

Vaccination with tumor peptide in CpG adjuvant protects via IFN-gamma-dependent CD4 cell immunity.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.055

7 January 2021

CpG are efficient adjuvants for specific CTL induction against tumor antigen-derived peptide

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.055

7 January 2021

Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.055

7 January 2021

Repeated administration of cytosine-phosphorothiolated guanine-containing oligonucleotides together with peptide/protein immunization results in enhanced CTL responses with anti-tumor activity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.055

7 January 2021

Combined dendritic cell- and CpG oligonucleotide-based immune therapy cures large murine tumors that resist chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.055

7 January 2021

NK- and CD8(+) T cell-mediated eradication of established tumors by peritumoral injection of CpG-containing oligodeoxynucleotides.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.055

7 January 2021

Divergent therapeutic and immunologic effects of oligodeoxynucleotides with distinct CpG motifs.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.055

7 January 2021

CpG motifs: the active ingredient in bacterial extracts?

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.055

7 January 2021

CpG DNA: a pathogenic factor in systemic lupus erythematosus?

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.055

7 January 2021

Natural selection of tumor variants in the generation of "tumor escape" phenotypes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.055

7 January 2021

Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.055

7 January 2021

Synergy between CpG- or non-CpG DNA and specific antigen for B cell activation

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.055

7 January 2021

DNA drives autoimmunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.055

7 January 2021

A role for Toll in autoimmunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.055

7 January 2021

Homeostasis and self-tolerance in the immune system: turning lymphocytes off.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.055

7 January 2021

T cell-independent rescue of B lymphocytes from peripheral immune tolerance

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.055

7 January 2021

Antigen-induced regulatory T cells in autoimmunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.055

7 January 2021

Altered immunoglobulin expression and functional silencing of self-reactive B lymphocytes in transgenic mice.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.055

7 January 2021

Induction of self-tolerance in mature peripheral B lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.055

7 January 2021

Whither the anergic B-cell?

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.055

7 January 2021

Breakdown of self-tolerance in anergic B lymphocytes.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.055

7 January 2021

Different nuclear signals are activated by the B cell receptor during positive versus negative signaling.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.055

7 January 2021

Breakdown of Tolerance to a Neo-Self Antigen in Double Transgenic Mice in Which B Cells Present the Antigen

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.055

7 January 2021

Determinant selection for T-cell tolerance in HEL-transgenic mice: dissociation between immunogenicity and tolerogenicity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.055

7 January 2021

The fate of self-reactive B cells depends primarily on the degree of antigen receptor engagement and availability of T cell help.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.055

7 January 2021

Rescue of self-reactive B cells by provision of T cell help in vivo

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.055

7 January 2021

Tolerance to a self-protein involves its immunodominant but does not involve its subdominant determinants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.055

7 January 2021

Resistance to CpG DNA-induced autoimmunity through tolerogenic B cell antigen receptor ERK signaling

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.055

7 January 2021

IL-1 receptor-associated kinase 1 regulates susceptibility to organ-specific autoimmunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.055

7 January 2021

Bacterial motif DNA as an adjuvant for the breakdown of immune self-tolerance to pyruvate dehydrogenase complex

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.055

7 January 2021

CpG-ODN-induced inflammation is sufficient to cause T-cell-mediated autoaggression against hepatocytes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.055

7 January 2021

A range of CD4 T cell tolerance: partial inactivation to organ-specific antigen allows nondestructive thyroiditis or insulitis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.055

7 January 2021

CpG-containing synthetic oligonucleotides promote B and cytotoxic T cell responses to protein antigen: a new class of vaccine adjuvants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.055

7 January 2021

CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.055

7 January 2021

Oral, intrarectal and intranasal immunizations using CpG and non-CpG oligodeoxynucleotides as adjuvants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.055

7 January 2021

Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.055

7 January 2021

Oligodeoxynucleotides without CpG motifs work as adjuvant for the induction of Th2 differentiation in a sequence-independent manner

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.055

7 January 2021

Identifiers

10.1016/J.VACCINE.2003.11.055

1 reference

Europe PubMed Central

14 January 2018

http://europepmc.org/abstract/MED/15193390

1 reference

Europe PubMed Central

14 January 2018

http://europepmc.org/abstract/MED/15193390

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q47356352&oldid=2153310976"